This is the text extract for Proposal to list Duolin HFA (salbutamol with ipratropium) aerosol inhaler - closes 26 September 2008, browse documents here.

9 September 2008

Proposal to list Duolin HFA (salbutamol with ipratropium) aerosol inhaler

Summary PHARMAC and Rex Medical Limited have signed a provisional agreement for the supply of a new brand of salbutamol with ipratropium aerosol inhaler, Duolin HFA. The agreement would result in this product being subsidised only if it attains registration by Medsafe. This proposal would not affect the listing of the current brand of this product, Combivent. Proposal If Duolin HFA attains registration by Medsafe, it would be listed in Section B of the Pharmaceutical Schedule at the following price and subsidy:

Chemical and strength Salbutamol 100 µg with 20 µg ipratropium Presentation Aerosol inhaler, CFC-free Pack size 200 doses OP Proposed price and subsidy $12.19

Duolin HFA would be protected from delisting until 1 July 2013, and from subsidy reduction until 1 July 2012. Feedback sought PHARMAC welcomes feedback on this proposal. To provide feedback please submit it in writing by 4 pm on Friday 26 September 2008 to: Sean Dougherty Therapeutic Group Manager PHARMAC PO Box 10 254 Wellington 6143 Email: sean.dougherty@pharmac.govt.nz Fax: 04 460 4995

All feedback received before the closing date will be considered by PHARMAC’s Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.

Page 1 of 1 A222577 – T08-189